Key facts
- Avasa’s last known valuation is $5.4M (Aug 2025).
- It has raised $4.4M; the latest was Later Stage VC ($2.8M) in Aug 2025.
- Notable investors include New Zealand Growth Capital Partners, Aspire NZ Seed Fund, Auckland UniServices, Booster Innovation Fund, Bridgewest Group — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Avasa
- ·The full record, as it builds
Funding rounds
No funding rounds for Avasa are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avasa
Developer of medical devices designed for reconstructive surgery. The company offers a proprietary device that standardizes vascular eversion to connect both arteries and veins in reconstructive microsurgery, enabling surgeons to reduce transplant failures and readmissions.
- Sector
- Healthcare
- HQ
- Auckland, New Zealand
- Founded
- 2018
- Employees
- 2
- Website
- avasa.io/
- Ownership
- Privately Held (backing)
Avasa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avasa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avasa in its N-PORT filings yet. We sweep new filings monthly.